Navigation Links
Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
Date:9/3/2014

0;is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning future actions relating to the development of PEGPH20 and the possibility that PEGPH20 may be used to address pancreatic cancer) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including delays in completion of clinical trials and other development activities, the possibility of safety events, unexpected expenditures and costs, unexpected results or delays in regulatory review, regulatory approval
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
2. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
3. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
4. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
5. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
6. Enrollment in Pharmatechs Revolutionary AccessPPM Program Launches
7. Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims
8. Raiing Medical and Partners HealthCares Center for Connected Health Initiate a Clinical Research Program for iThermonitor
9. Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs
10. AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards
11. GRANDCARE SYSTEMS Announces Significant Investment in Professional Caregiving Sales Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... More than 1,500 substance abuse prevention and treatment specialists ... Indianapolis Aug. 2-6 for Community Anti-Drug Coalitions ... The week-long training, held at the JW Marriott, will ... biggest public health challenges – youth drug use. ... intensive training opportunity, offering more than 70 half-day and ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Market by Product (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, ... & End User (Hospitals, Pharmaceuticals) - Global Forecast to 2020", ... reach around USD 6.1 Billion by 2020, at a CAGR ... 242 market data T ables and ...
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... communicate. Rally Insurance Group, Inc. has re-branded their social media profiles to better ... personal way for consumers to communicate, find information, share insights and opinions. The ...
(Date:7/31/2015)... ... , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection ... exam easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... 16 The non-profit,organization Women in Government presented ... Association today at the John F.,Kennedy Center for ... Pennsylvania and nine other states for launching a ... Lieutenant Governor Knoll accepted the award on behalf ...
... New Rankings Show No City Is Allergy-Free, WASHINGTON, Nov. ... this fall, and some cities are much worse than others,according ... Asthma and,Allergy Foundation of America (AAFA). The Foundation recently announced ... was,crowned "the most challenging place to live with fall allergies" ...
... Inc.,(Nasdaq: HOLX ), a diversified diagnostic and medical ... of women, today announced,the Company will host a meeting ... the RSNA (Radiological Society of North America) trade,show in ... November 27, 2007, at McCormick,Place from 8:00 - 10:00 ...
... /PRNewswire/ Dilon Technologies, Inc. a,United States manufacturer and ... of Scott Yarde for the position of,Vice President ... Yarde joins Dilon to provide leadership in national ... track record with 25,years of sales, marketing and ...
... to Impose Stiffer Penalties, ... State Investigators, CLAREMONT, Calif., Nov. 16 ... action lawsuit against Health Net,Life Insurance Company, alleging ... insurance policies has needlessly placed the,lives of hundreds ...
... at six sites nationwide , FRIDAY, Nov. 16 ... the genetic and environmental factors that may cause autism, ... 2,700 children and their families from six areas in ... Development -- which researchers called the largest of its ...
Cached Medicine News:Health News:Austin Named the New 'Fall Allergy Capital' 2Health News:Hologic, Inc. to Host Investor Reception at the RSNA Trade Show 2Health News:Dilon Technologies Appoints New VP of Sales & Business Development 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 3Health News:Major U.S. Autism Study Gets Under Way 2
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
Medicine Products: